Audited Financial Results for the Quarter and Year ended on March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bharat Parenterals reported mixed results for FY26. On a standalone basis, revenue declined 23% to ₹234 crore from ₹304 crore, while net profit fell 39% to ₹16 crore. The company declared a dividend of ₹1 per share. On a consolidated basis, the group reported a net loss of ₹27.3 crore, though this is an improvement from the previous year's loss of ₹43.7 crore. Consolidated revenue remained flat at ₹345 crore. EBITDA margin expanded on a consolidated basis (from 0.79% to 4.58%) but compressed on standalone (from 11.05% to 9.01%). Non-current borrowings increased significantly from ₹7.6 crore to ₹12.2 crore, indicating higher leverage. The statutory auditors issued an unmodified opinion on both standalone and consolidated results.
The standalone revenue decline and consolidated net loss are concerning for shareholders. The increase in debt levels raises concerns about financial leverage. However, the narrowing of consolidated losses and improved operating cash flow may offer some comfort.